{"id":92088,"date":"2026-05-26T01:23:41","date_gmt":"2026-05-26T01:23:41","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/92088\/"},"modified":"2026-05-26T01:23:41","modified_gmt":"2026-05-26T01:23:41","slug":"assessing-novo-nordisk-cpsenovo-b-valuation-after-eu-boost-for-wegovy-oral-pill","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/92088\/","title":{"rendered":"Assessing Novo Nordisk (CPSE:NOVO B) Valuation After EU Boost For Wegovy Oral Pill"},"content":{"rendered":"\n

Find your next quality investment<\/a> with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.<\/p>\n

The recent positive opinion from the EMA\u2019s Committee for Medicinal Products for Human Use on the Wegovy pill has pushed Novo Nordisk (CPSE:NOVO B) back into focus for investors watching obesity and cardiovascular treatments.<\/p>\n

See our latest analysis for Novo Nordisk.<\/a><\/p>\n

These Wegovy updates have arrived during a strong short term rebound in Novo Nordisk\u2019s share price, with a 30 day share price return of 11.18% and 90 day return of 18.61%. However, the year to date share price return is down 12.49% and the 1 year total shareholder return is down 34.31%, which together suggest recent momentum is improving after a tougher period for long term holders.<\/p>\n

If the obesity and cardiovascular story has caught your attention, it can be worth widening your lens to other healthcare and weight loss related opportunities using our healthcare focused AI stock screener, starting with 128 healthcare AI stocks<\/a>.<\/p>\n

With Wegovy\u2019s oral pill moving closer to EU approval and Novo Nordisk\u2019s earnings beating recent expectations, the stock now trades at a modest discount to analyst targets. Is there still value on the table, or is potential future performance already reflected in the current price?<\/p>\n

Most Popular Narrative: 66% Undervalued <\/p>\n

Tokyo\u2019s widely followed narrative pegs Novo Nordisk\u2019s fair value at DKK851.04 per share versus the last close of DKK289, pointing to a large valuation gap based on long term assumptions about growth, profitability and the cost of capital.<\/p>\n

With the unexpected success of its obesity drugs, the company has effectively gained a highly profitable new business segment almost for free, built on the same scientific platform. This windfall is now driving massive capital inflows, which Novo Nordisk is wisely reinvesting to secure its leadership for decades to come.<\/p>\n

Read the complete narrative.<\/a><\/p>\n

Curious what has to happen for that higher fair value to make sense? This narrative leans on faster revenue expansion, firm margins and a richer earnings multiple. The exact mix behind that DKK851.04 figure might surprise you.<\/p>\n

Result: Fair Value of DKK851.04 (UNDERVALUED)<\/p>\n

Have a read of the narrative in full and understand what’s behind the forecasts.<\/a><\/p>\n

However, this upbeat story still faces pressure points, including potential regulatory pushback on obesity treatments and any slowdown or pricing pressure in the key Diabetes and Obesity Care segment.<\/p>\n

Find out about the key risks to this Novo Nordisk narrative.<\/a><\/p>\n

Next Steps <\/p>\n

With mixed views on risks and rewards running through this story, the next move is yours. Review the data closely and weigh up the 3 key rewards and 4 important warning signs.<\/p>\n

Looking for more investment ideas? <\/p>\n

If you are serious about compounding returns, do not stop at a single stock. Use targeted screeners to turn today\u2019s research into a broader watchlist.<\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.<\/p>\n

Companies discussed in this article include NOVO-B.CO<\/a>.<\/p>\n

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million…\n","protected":false},"author":2,"featured_media":92089,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[48388,272,9496,948,3475,1739],"class_list":["post-92088","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-emas-committee-for-medicinal-products-for-human-use","tag-novo-nordisk","tag-obesity-treatments","tag-share-price","tag-stock-screener","tag-total-shareholder-return"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116638266530286396","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/92088","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=92088"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/92088\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/92089"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=92088"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=92088"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=92088"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}